COVID-19 Clinical Trials and Expanded Access

This study is aimed to investigate the treatment vitamin D3 as complementary therapy withroutine care for early mild symptoms of COVID-19 in outpatients setting.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a worldwide pandemicin over 100 years. The disease caused by this newly discovered virus was called Covid-19.In this study, we aimed to evaluate changing of PSA value in patients with Covid-19.

Healthcare workers (HCWs) play a vital role in determining the success of vaccinationprograms. Patient acceptance and vaccination rely greatly on the utilization and attitudeof HCWs towards the vaccine, their attitude also influences patients' adherence tovaccination schedules and their hesitancy. HCWs themselves can be hesitant about acertain vaccine and thus can transfer their negative attitudes to their patients,increasing vaccine hesitancy among the general population. Frontline HCWs are at anincreased risk of exposure to COVID-19 due to their direct contact with their patients,working hours, psychological stress and job burnout, they also face stigma. Dental healthprofessionals in particular are at an increased risk due to their occupational hazardsthat include continuous exposure to body fluids and aerosols, this increases their riskof contracting COVID-19. Therefore vaccinating healthcare workers will be beneficial, notonly for themselves, but also for their households and patients.

In recent months, more and more studies suggest tele-rehabilitation as a means to beexploited to reduce the risk of contagion.The intent of our study is to verify the effectiveness of a tele-rehabilitationintervention through the application of a respiratory rehabilitation program supported bycontact with physiotherapists, in patients with outcomes from SARS-CoV-2 infectiondischarged from the various medical departments and taken over by physiotherapists afterphysiatric evaluation.Faced with the same rehabilitation program prescribed to all patients, the primaryobjective of our study is to detect whether patients supported by remote rehabilitationafter hospitalization improve both adherence to the rehabilitation program andcardiorespiratory endurance and dyspnea symptoms assessed with the Six Minute WalkingTest scale (6MWT). This test is validated for multiple pathologies, including idiopathicpulmonary fibrosis, the clinic of which could be comparable to the outcomes ofcoronavirus interstitial pneumonia as suggested by the literature.The secondary objectives concern the assessment of the impact of physical exerciseassisted by tele-rehabilitation detected through: the assessment of the quality of life(Saint George Respiratory Questionnaire );the assessment of autonomy in daily lifeactivities (Barthel Index Dyspnea Scale), the evaluation of the variation in thoracicexpansion and lung volumes (with COACH , an instrument for respiratory physiotherapy thatmeasures the inspiratory volume in ml); the evaluation of muscle strength and endurance(One Minute Sit To Stand) ; the detection of dyspnea during the execution of theexercises (Modified Borg scale); the assessment of the functionality of the lower limbs(Short Physical Performance Battery)

On 11 February 2020, the International Committee for the Classification of Viruses namedthe disease caused by SAＲS-CoV-2 infection in humans as the new coronavirus pneumonia(coronavirus disease 2019, COVID-19). Due to the characteristics of livermicrocirculation disturbance and immune function disorder in patients with chronic liverdiseases (such as immune liver disease, chronic hepatitis C, liver cirrhosis, livercancer, etc.), those patients has a higher risk of infection than the general populationduring the epidemic period. More attention should be paid to personal protection anddisease prevention. Vaccination of COVID-19 vaccine can effectively prevent COVID-19virus infection and delay or prevent patients from developing into critical illness andreduce mortality. To evaluate the safety and effectiveness of COVID-19 vaccine in thosepatients with chronic liver diseases, and to guide the COVID-19 vaccination morescientifically, reasonably and effectively, this study was carried out.

A randomized, double-blind, placebo -controlled, phase IIb clinical trial to evaluate theefficacy, safety and immunogenicity of one or two doses of Recombinant Novel CoronavirusVaccine (Adenovirus Type 5 Vector) in adults 18 years of age and older, living with HIV,on stable treatment, and virologically suppressed for at least 6 monthsProtocol number: FH-58

This will be a prospective observational study of lactating mothers who are planning to,have scheduled or have received vaccination against SARS-COV-2 (COVID-19 vaccine).Mothers may have delivered at Mount Sinai Hospital or may be from the general publicrecruited by social media or word of mouth. As the study participants will be lactatingmothers, they will not be under the care of the investigators. Due to lack ofinformation, we are unsure of an appropriate sample size but envision we will recruit atleast 10 women each immunized with the approved mRNA vaccines (e.g. Pfizer-BioNTech andModerna COVID-19 vaccines) and in the future at least two other vaccines (e.g.Oxford-AstraZeneca) as they are approved and become available. Milk samples will beanalyzed for the presence of antibody to SARS-CoV-2 using the Anti-SARS-CoV-2 ELISA (IgGand IgA). These analyses will be conducted in the Department of Microbiology at SinaiHealth following validation of the procedures in human milk.

This study is a randomized, double-blinded, and placebo controlled phase Ⅰ clinical trialof the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of theexperimental vaccine in healthy population aged 3 to 17 years.

This study is a randomized, double-blinded, and placebo controlled phase Ⅱ clinical trialof the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of theexperimental vaccine in healthy population aged 3 to 17 years.

This study is a longitudinal cohort study which investigates the effect of COVID-19 inambulatory care. This study aims to assess the effect of COVID-19 beyond the acute phase,i.e. on long-term symptoms, respiratory and cardiovascular health, use of healthservices, and quality of life.